Respiratory Virus Multiplex RT-PCR Assay Sensitivities and Influence Factors in Hospitalized Children with Lower Respiratory Tract Infections*

Jikui Deng¹,³, Zhuoya Ma¹, Wenbo Huang², Chengrong Li¹, Heping Wang¹, Yuejie Zheng¹, Rong Zhou² and Yi-Wei Tang³

¹. Shenzhen Children’s Hospital, Chongqing Medical University, Shenzhen 518026, China; ². State Key Laboratory of Respiratory Diseases, Guangzhou Medical University, Guangzhou, Guangdong 510230, China; ³. Department of Laboratory Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA

Multiplex RT-PCR assays have been widely used tools for detection and differentiation of a panel of respiratory viral pathogens. In this study, we evaluated the Qiagen ResPlex II V2.0 kit and explored factors influencing its sensitivity. Nasopharyngeal swab (NPS) specimens were prospectively collected from pediatric inpatients with lower respiratory tract infections at the time of admission in the Shenzhen Children’s Hospital from May 2009 to April 2010. Total nucleic acids were extracted using the EZ1 system (Qiagen, Germany) and 17 respiratory viruses and genotypes including influenza A virus (FluA), FluB, parainfluenza virus 1 (PIV1), PIV2, PIV3, PIV4, respiratory syncytial virus (RSV), human metapneumovirus (hMPV), rhinoviruses (RhV), enteroviruses (EnV), human bocaviruses (hBoV), adenoviruses (AdV), four coronaviruses (229E, OC43, NL63 and HKU1), and FluA 2009 pandemic H1N1(H1N1-p) were detected and identified by the ResPlex II kit. In parallel, 16 real-time TaqMan quantitative RT-PCR assays were used to quantitatively detect each virus except for RhV. Influenza and parainfluenza viral cultures were also performed. Among the total 438 NPS specimens collected during the study period, one or more viral pathogens were detected in 274 (62.6%) and 201 (45.9%) specimens by monoplex TaqMan RT-PCR and multiplex ResPlex, respectively. When results from monoplex PCR or cell culture were used as the reference standard, the multiplex PCR possessed specificities of 92.9-100.0%. The sensitivity of multiplex PCR for PIV3, hMPV, PIV1 and BoV were 73.1%, 70%, 66.7% and 55.6%, respectively, while low sensitivities (11.1%-40.0%) were observed for FluA, EnV, OC43, RSV and H1N1. Among the seven viruses/genotypes detected with higher frequencies, multiplex PCR sensitivities were correlated significantly with viral loads determined by the TaqMan RT-PCR in FluA, H1N1-p and RSV ($p=0.011-0.000$).

The Qiagen ResPlex II multiplex RT-PCR kit possesses excellent specificity for simultaneous detection of 17 viral pathogens in NPS specimens in pediatric inpatients at the time of admission. The sensitivity of multiplex RT-PCR was influenced by viral loads, specimen process methods, primer and probe design and amplification condition.

Multiplex RT-PCR; Respiratory viral loads; Cell culture; Lower respiratory tract infection

*  Foundation items: This study was supported in part by Grant Name awarded to the State Key Lab of Respiratory Diseases, Guangzhou Medical College (2007DA780154F0910).
** This study was presented in part at the Association for Molecular Pathology Annual Meeting, Long Beach, CA, October 25-27, 2012.

Corresponding authors.
Rong Zhou: Phone: +86-20-83337750, Fax: +86-20-83062729, Email: zhou3218@yahoo.com.
Yi-Wei Tang: Phone: +1-212-639-8181, Fax: +1-646-422-2061, Email: tangy@mskcc.org

Lower respiratory tract infections (LRTIs) are the most frequent cause of hospitalization among children worldwide (Ahn K M, et al., 1999; Garbino J, et al., 2004; Ruuskanen O, et al., 2011; Sung C C, et al., 2011; Thompson W W, et al., 2003; van Woensel J B, et al., 2003). A large proportion of LRTIs are caused by respiratory viruses including influenza virus A (FluA) and B (FluB), parainfluenza viruses 1-4 (PIV1-4), respiratory syncytial virus (RSV), rhinoviruses (RhV), enteroviruses (EnV), and adenoviruses (AdV) (Juven T, et al., 2000; Legg J P, 2000; Sung C C, et al., 2011).
et al., 2005; Weigl J A, et al., 2005). Over the past decade, the viral pathogen list has been expanded to several newly discovered viruses including human metapneumovirus (hMPV) (van den Hoogen B G, et al., 2001), some coronaviruses (NL63, HKU1, SARS) (Pyrc K, et al., 2007), human bocaviruses (hBoV) (Allander T, et al., 2005), and pandemic influenza A/H1N1 2009 virus (H1N1-p) (Anonymous, 2009). Various viruses with different shedding levels may result in a large disease severity range from common bronchitis to fatal pneumonia (Li C C, et al., 2010; Martin E T, et al., 2012; Takeyama A, et al., 2012; Torres J P, et al., 2010).

Rapid and accurate etiologic diagnosis of LRTIs is essential to patient management. Several multiplex RT-PCR-based devices are commercially available for detection and differentiation of a panel of respiratory viral pathogens (Zhang S, et al., 2011). They are being increasingly used in the clinical setting as a cornerstone technique in the clinical virology laboratory as they possess sensitivities greater than rapid viral antigen testing and test turnaround time shorter than standard respiratory virus culture (Balada-Llasat J M, et al., 2011; Kim S R, et al., 2009; Rand K H, et al., 2011; Schindera C, et al., 2010). Varying sensitivities have been reported between different devices for specific viral pathogens in different studies (Balada-Llasat J M, et al., 2011; Kim S R, et al., 2009; Rand K H, et al., 2011; Schindera C, et al., 2010). In this study, we evaluated the ResPlex II V2.0 kit (Qiagen, Germany), which uses a target enriched multiplexing RT-PCR amplification coupled with a suspension array detection, for detection and identification of a panel of respiratory specimens in pediatric inpatients with LRTIs.

Monoplex real-time TaqMan RT-PCR

One NPS aliquot was sent to the State Key Laboratory of Respiratory Diseases of the Guangzhou Medical University where several quantitative monoplex real-time TaqMan RT-PCR assays were performed as previously described (Liu W K, et al., 2011). Pathogens detected individually by this platform included FluA, H1N1-p, FluB, PIV1, PIV2, PIV3, PIV4, RSV, hMPV, EnV, hBoV, AdV, four coronaviruses (229E, OC43, NL63 and HKU1) as well as two atypical bacterial pathogens (Mycoplasma pneumonia and Chlamydia pneumonia). Total nucleic acids from NPS were extracted using a QIAamp MinElute virus Kit (Qiagen, Germany), in accordance with the manufacturer’s protocol and previously described (Seferis S E, et al., 2006). Primers and the probe were synthesized by TaKaRa (Dalian, China). One step RT-PCR reaction buffer (PrimeScript One Step RT-PCR Kit Ver.2) was also purchased from TaKaRa. Amplification was conducted using 10 pmol of primers, 3 pmol of probe and 5 μL.
specimen extract in a final volume of 25 μL on the ABI-7500 real-time PCR instrument (Applied Biosystems, Foster City, CA). Cycling conditions included an initial incubation at 50 °C for 30 min, 94 °C for 2 min, followed by 40 cycles of 94 °C for 10 sec and 55 °C for 35 sec (Liu W K, et al., 2011). The amplified gene target sequence was inserted into the pMD18-T vector (TaKaRa) and used as a positive control for quantification analysis. Sensitivity of the PCR assay was calculated to be 10 copies of plasmid DNA using positive control plasmid diluted titrations. Five standards covering viral loads from 10-100,000 copies/mL were included to generate a quantification standard curve for absolute viral load determination of each tested NPS specimen.

ResPlex II Panel v2.0 (ResPlex)

One NPS aliquot was used for a panel of respiratory viral pathogen detection by the ResPlex II Panel (Qiagen, Germany) (Li H, et al., 2007). Version 2.0 covers viruses and types of FluA, FluB, RSV, PIV1, PIV2, PIV3, PIV4, hMPV, coxsackieviruses/echoviruses, RhV, human bocaviruses, adenoviruses B and E, and four coronaviruses (NL63, HUK1, 229E, and OC43). A newer version (ResPlex II plus panel PRE) was used later in the study which also includes FluA 2009 pandemic H1N1 (H1N1-p). Total nucleic acids were extracted from 200 μL of NPS specimen using the Qiaamp Q-card EZ1 virus mini kit (Cat. No.955314) in an EZ1 Extraction System and eluted in 50 μL of water. The RT-PCR amplification was performed on the ABI-7500 real-time PCR System with 10 μL of extract included in each reaction. The amplification product was then detected and identified by using a suspension bead array for multiplex hybridization in the LiquiChip 200 Workstation with the QIAplex MDD Software (Qiagen, Germany). Controls were included on each test run including a positive control (in vitro transcribed RNA corresponding to a human genomic DNA sequence), an internal control to check for viral RNA isolation and PCR inhibition, and a sample control to detect traces of human genomic DNA present in each specimen. A positive result was determined using a cut-off median fluorescence intensity (MFI) of 250 or the mean plus 2 standard deviations of the negative controls (Gharabaghi F, et al., 2011).

Statistical analysis

The combined results of the viral culture and monoplex real time RT-PCR was used as a reference standard. A sample was determined to be positive for the tested virus when viral culture or real time RT-PCR was positive. For comparison of qualitative categorical data, χ² test or Fisher’s exact test and Mantel-Haenszel χ² test were used wherever appropriate. A p<0.05 was considered statistically significant. Trend analysis and rank test was used to determine the correlations between ResPlex assay sensitivities and viral loads.

### Table 1. The comparison of ResPlex (R) and monoplex real-time TaqMan RT-PCR (M) for 16 respiratory viruses *

| Virus  | No. detected | Sensitivity (%) | Specificity (%) | PPV (%) | NPV (%) |
|--------|--------------|----------------|----------------|---------|---------|
| RSV    | M+R+ 46      | 33.3           | 98             | 88.5    | 76.2    |
|        | M+R- 92      |                |                |         |         |
|        | M-R+ 6       |                |                |         |         |
|        | M-R- 294     |                |                |         |         |
| FluA   | M+R+ 4       | 11.1           | 99.5           | 66.7    | 92.6    |
|        | M+R- 32      |                |                |         |         |
|        | M-R+ 2       |                |                |         |         |
|        | M-R- 400     |                |                |         |         |
| hMPV   | M+R+ 21      | 70             | 99.3           | 87.5    | 97.8    |
|        | M+R- 9       |                |                |         |         |
|        | M-R+ 3       |                |                |         |         |
|        | M-R- 405     |                |                |         |         |
| PIV3   | M+R+ 19      | 73.1           | 98.9           | 79.2    | 98.4    |
|        | M+R- 7       |                |                |         |         |
|        | M-R+ 5       |                |                |         |         |
|        | M-R- 407     |                |                |         |         |
| H1N1-p** | M+R+ 10      | 40             | 100            | 100     | 95.1    |
|        | M+R- 15      |                |                |         |         |
|        | M-R+ 0       |                |                |         |         |
|        | M-R- 289     |                |                |         |         |
| PIV1   | M+R+ 12      | 66.7           | 99.3           | 80      | 98.6    |
|        | M+R- 6       |                |                |         |         |
|        | M-R+ 3       |                |                |         |         |
|        | M-R- 417     |                |                |         |         |
| hBoV   | M+R+ 10      | 55.6           | 100            | 100     | 98.1    |
|        | M+R- 8       |                |                |         |         |
|        | M-R+ 0       |                |                |         |         |
|        | M-R- 420     |                |                |         |         |
| OC43   | M+R+ 4       | 26.7           | 99.8           | 80      | 97.5    |
|        | M+R- 11      |                |                |         |         |
|        | M-R+ 1       |                |                |         |         |
|        | M-R- 422     |                |                |         |         |
| EnV    | M+R+ 2       | 14.3           | 92.9           | 6.3     | 97      |
|        | M+R- 12      |                |                |         |         |
|        | M-R+ 30      |                |                |         |         |
|        | M-R- 394     |                |                |         |         |
| ADV    | M+R+ 4       | 57.1           | 100            | 100     | 99.3    |
|        | M+R- 3       |                |                |         |         |
|        | M-R+ 0       |                |                |         |         |
|        | M-R- 431     |                |                |         |         |
| NL63   | M+R+ 3       | 50             | 99.8           | 75      | 99.3    |
|        | M+R- 3       |                |                |         |         |
|        | M-R+ 1       |                |                |         |         |
|        | M-R- 431     |                |                |         |         |
| 229E   | M+R+ 3       | 60             | 99.8           | 75      | 99.5    |
|        | M+R- 2       |                |                |         |         |
|        | M-R+ 0       |                |                |         |         |
|        | M-R- 432     |                |                |         |         |
| FluB   | M+R+ 2       | 50             | 100            | 100     | 99.5    |
|        | M+R- 2       |                |                |         |         |
|        | M-R+ 0       |                |                |         |         |
|        | M-R- 434     |                |                |         |         |
| PIV4   | M+R+ 2       | 66.7           | 99.8           | 66.7    | 99.8    |
|        | M+R- 1       |                |                |         |         |
|        | M-R+ 1       |                |                |         |         |
|        | M-R- 434     |                |                |         |         |
| PIV2   | M+R+ 0       | NA             | 100            | NA      | 99.3    |
|        | M+R- 3       |                |                |         |         |
|        | M-R+ 0       |                |                |         |         |
|        | M-R- 435     |                |                |         |         |
| HKU1   | M+R+ 0       | NA             | NA             | NA      | NA      |
|        | M+R- 0       |                |                |         |         |
|        | M-R+ 0       |                |                |         |         |
|        | M-R- 438     |                |                |         |         |

* RhV was not evaluated as it was not detected by the monoplex real-time RT-PCR. PPV, positive predictive value; NPV, negative predictive value. ** The Resplex II Panel v2.0 was replaced by a Resplex II Plus Panel PRE to enhance H1N1-P coverage during the study. A total of 314 samples were tested by the Resplex II Plus Panel PRE version.
Table 2. Relationship of sensitivity of ResPlex PCR and viral loads determined by monoplex PCR

| Monoplex copies/mL | No. of ResPlex-PCR positive/No. of Monoplex PCR positive |
|--------------------|--------------------------------------------------------|
|                    | RSV (%) | FluA (%) | hMPV (%) | PIV3 (%) | H1N1-p (%) | PIV1 (%) | hBoV (%) |
| ≥ 10^6             | 6/9 (66.7) | 1/1 (100) | 3/4 (75.0) | 2/3 (66.7) | 4/5 (80.0) | 0/0 (0) | 9/11 (81.8) |
| 1-9.9×10^3         | 34/45 (75.5) | 2/5 (40.0) | 10/14 (71.4) | 8/8 (100.0) | 5/6 (83.3) | 5/5 (100.0) | 1/3 (33.3) |
| 1-9.9×10^4         | 5/38 (13.2) | 1/7 (14.3) | 6/9 (66.7) | 4/5 (80.0) | 1/6 (16.7) | 6/7 (85.7) | 0/2 (0) |
| 1-9.9×10^5         | 1/33 (3.0) | 0/12 (0) | 2/3 (66.7) | 2/4 (50.0) | 0/6 (0) | 1/3 (33.3) | 0/1 (0) |
| 1-9.9×10^6         | 0/13 (0) | 0/11 (0) | 0/0 (0) | 3/6 (50.0) | 0/2 (0) | 0/3 (0) | 0/1 (0) |
| Negative            | 6/300 (2.0) | 2/402 (0.5) | 3/408 (0.7) | 5/412 (1.2) | 0/289 (0) | 3/420 (0.7) | 0/420 (0) |

RESULTS

A total of 438 qualified NPS specimens collected during a one full year study period were included in the final testing and analysis. The male ratio was 77.6%. The mean age of patients was 1.4 years, ranging from one month to 11 years. Among the total specimens tested, 263 (60.0%), 134 (30.6%) and 41 (9.4%) were from children of <1, 1-3 and >3 years old, respectively.

Among the total 438 NPS specimens, one or more viral pathogens were detected in 274 (62.6%) and 201 (45.9%) specimens by monoplex TaqMan RT-PCR and multiplex ResPlex RT-PCR, respectively. Viral culture was positive for 56 (12.8%) specimens including 17 FluA, 3 FluB, 14 PIV1, and 22 PIV3. Among these culture positive specimens, monoplex real-time TaqMan RT-PCR results were fully concordant while ResPlex results were negative for 13 specimens including six FluA, four PIV1 and three PIV3. When results from monoplex RT-PCR or cell culture were used as the reference standard, the multiplex PCR possessed specificities ranging from 92.9% to 100.0% for the viruses tested. The sensitivities of multiplex PCR varied with high sensitivity observed for PIV3, hMPV, PIV1 and hBoV (55.6-73.1%) and low sensitivity for FluA, EnV, OC43, RSV and H1N1-p (11.1-40.0%) (Table 1).

Rhinoviruses were detected from 36 specimens (8.3%) by the ResPlex assay including 22 rhinovirus alone and 14 co-detected with other viruses including Rhv/EnV (n=10), Rhv/RSV (n=2), Rhv/hMPV (n=1), and Rhv/229E (n=1). Since rhinoviruses were not detected by the monoplex TaqMan RT-PCR, these data were not further analyzed.

We further correlated viral load information determined by the TaqMan RT-PCR with the ResPlex diagnostic sensitivities for seven viruses/genotypes detected with higher frequencies (positive rate >4% detected by monoplex RT-PCR). The ResPlex multiplex PCR sensitivities correlated significantly with viral loads for RSV, FluA and H1N1-p (p=0.011-0.000). Significant correlation was not observed for PIV1, PIV3, hBoV, and hMPV (p>0.05) (Table 2).

During the study, a new version of ResPlex, ResPlex II Plus Panel PRE, was manufactured to increase coverage of H1N1-p. There were 124 and 314 specimens which were tested by ResPlex II Panel and ResPlex II Plus Panel PRE, respectively (Table 1). For the seven non-H1N1-p viruses/genotypes detected with higher frequencies, the sensitivities dropped (range from 3.6% to 43.7%) for five viruses including FluA, RSV, hBoV, PIV1 and PIV3. The

Table 3. Sensitivity of two kinds of ResPlex II kit for common viruses *

| Virus | No. of specimens | Sensitivity (%) | No. of specimens | Sensitivity (%) |
|-------|------------------|----------------|------------------|----------------|
|       | Resplex II Panel | M+R+ | M+R- | M-R+ | M-R- | Resplex II Plus Panel PRE | M+R+ | M+R- | M-R+ | M-R- |
| RSV   | 14               | 35.9 | 32   | 3    | 212  | 32.3 | 0.161 | 0.688 |
| FluA  | 2                | 50.0 | 2    | 30   | 0    | 6.5  | 6.891 | 0.053 |
| hMPV  | 4                | 50.0 | 17   | 5    | 1    | 77.3 | 2.078 | 0.195 |
| PIV3  | 6                | 100.0| 13   | 7    | 3    | 65.0 | 2.874 | 0.146 |
| PIV1  | 3                | 100.0| 9    | 6    | 1    | 60.0 | 1.80  | 0.515 |
| hBoV  | 5                | 83.3 | 5    | 7    | 0    | 41.7 | 2.813 | 0.152 |

* R, Resplex II Panel; M, monoplex real-time TaqMan RT-PCR.
sensitivity increased only for hMPV (Table 3). None of these sensitivity differences reached statistical significance by χ² or Fisher’s exact test (p=0.05). When the Mantel-Haenszel χ² test was used for the combined strata analysis, no significant difference was observed (χ²M-H=2.676, p=0.102).

DISCUSSION

Several multiplex RT-PCR-based devices have been commercially available for detection and identification of a panel of viral pathogens causing LRTIs. We evaluated one of the platforms (ResPlex II), which combines a target enriched multiplexing RT-PCR amplification and a suspension array detection (Balada-Llasat J M, et al., 2011; Li H, et al., 2007), using prospectively collected NPS specimens from pediatric inpatient patients with clinical diagnosis of LRTIs. The ResPlex II multiplex RT-PCR kit possessed excellent specificity and varied sensitivities ranging from 11.1 to 73.1%, but which was relatively lower than two recently reported studies on children populations (Forman M S, et al., 2012; Hayden R T, et al., 2012).

Significantly lower sensitivities by the ResPlex II assay were observed especially for FluA, EnV, OC43, RSV and H1N1-p. We observed the following factors which might explain the discrepancies between our and previously reported studies. First, based on the patient populations and reference standards, the test sensitivities could vary significantly. Mak G et al (Mak G C, et al., 2011) reported the sensitivity of ResPlex II for FluA and H1N1-p were only 31.8% and 42.9% when monoplex RT-PCR was used for comparison. However in previous studies in which virus culture or DFA was used as the RT-PCR was used for comparison. When the Mantel-Haenszel χ² test was used for the combined strata analysis, no significant difference was observed (χ²M-H=2.676, p=0.102).

Previous studies revealed that the detection of FluA (H1N1) viruses correlated with the time after symptom onset and viral load (Cheng P K, et al., 2010). In our study, among the seven viruses/genotypes detected with higher frequencies, ResPlex II sensitivities correlated significantly with viral loads determined by the TaqMan RT-PCR in RSV, FluA and H1N1-p. In contrast, no viral load correlation was observed in PIV3, hMPV, PIV1 and hBoV. Since viral load did not correlate with lower sensitivities for some of the targets, the PCR amplification and hybridization efficiencies may also play a role. It is reasonable that multiplex PCR sensitivities decreased with decreasing viral load of target virus. In the ResPlex II, primers and probes were designed from the F genome of hMPV in which significant sequence variations were revealed by the recent finding of four geno/ subtypes (Mackay I M, et al., 2006). Whether the poor correlation between viral load and PCR sensitivity in hMPV is related to the primer/probe design merits further investigation. Varied analytical sensitivities were noticed in other viral targets in a recent study in immunocompromised children (Hayden R T, et al., 2012).

References

Ahn K M, Chung S H, Chung E H, Koh Y J, Nam S Y, Kim J H, Son J A, Park J Y, Lee N Y, and Lee S I. 1999. Clinical characteristics of acute viral lower respiratory tract infections in hospitalized children in Seoul, 1996-1998. J Korean Med Sci, 14: 405-411.

Allander T, Tammi M T, Eriksson M, Bjerkner A, Tiveljung-Lindell A, and Andersson B. 2005. Cloning of a human parvovirus by molecular screening of respiratory tract samples. Proc Natl Acad Sci U S A, 102: 12891-12896.

Anonymous. 2009. Swine influenza A (H1N1) infection in two children--Southern California, March-April 2009. MMWR Morb Mortal Wkly Rep, 58: 400-402.

Balada-Llasat J M, LaRue H, Kelly C, Rigali L, and Pancholi P. 2011. Evaluation of commercial ResPlex II v2.0, MultiCode-PLx, and xTAG respiratory viral panels for the diagnosis of respiratory viral infections in adults. J Clin Virol, 50: 42-45.

Cheng P K, Wong K K, Mak G C, Wong A H, Ng A Y, Chow S Y, Lam R K, Lau C S, Ng K C, and Lim W. 2010. Performance of laboratory diagnostics for the detection of influenza A(H1N1)v virus as correlated with the time after symptom onset and viral load. J Clin Virol, 47: 182-185.

Forman M S, Advani S, Newman C, Gaydos C A, Milstone A M, and Valsamakis A. 2012. Diagnostic performance of two highly multiplexed respiratory virus assays in a pediatric cohort. J Clin Virol, 55: 168-172.

Garbino J, Gerbase M W, Wunderli W, Kolarova L, Nicod L P, Rochat T, and Kaiser L. 2004. Respiratory viruses and severe lower
respiratory tract complications in hospitalized patients. Chest, 125: 1033-1039.

Gharabaghi F, Hawan A, Drews S J, and Richardson S E. 2011. Evaluation of multiple commercial molecular and conventional diagnostic assays for the detection of respiratory viruses in children. Clin Microbiol Infect, 17: 1900-1906.

Hayden R T, Gu Z, Rodriguez A, Tanioka L, Ying C, Morganstem M, and Bankowski M J. 2012. Comparison of two broadly multiplexed PCR systems for viral detection in clinical respiratory tract specimens from immunocompromised children. J Clin Virol, 53: 308-313.

Juven T, Mertsola J, Waris M, Leinonen M, Meurmann O, Roivainen M, Eskola J, Saikku P, and Ruuskanen O. 2000. Etiology of community-acquired pneumonia in 254 hospitalized children. Pediatr Infect Dis J, 19: 293-298.

Kim S R, Chi C S, and Lee N Y. 2009. Rapid detection and identification of 12 respiratory viruses in clinical specimens by immunofluorescence staining. J Clin Microbiol, 38: 708-711.

Legg J P, Warner J A, Johnston S L, and Warner J O. 2005. Frequency of detection of picornaviruses and seven other respiratory pathogens in infants. Pediatr Infect Dis J, 24: 611-616.

Li C C, Wang L, Eng H L, You H L, Chang L S, Tang K S, Lin Y J, Kuo H C, Lee I K, Liu J W, Huang E Y, and Yang K D. 2010. Correlation of pandemic (H1N1) 2009 viral load with disease severity and prolonged viral shedding in children. Emerg Infect Dis, 16: 1265-1272.

Li H, McCormac M A, Estes R W, Sefers S E, Dare R K, Chappell J D, Erdman D D, Wright P F, and Tang Y W. 2007. Simultaneous detection and high-throughput identification of a panel of RNA viruses causing respiratory tract infections. J Clin Microbiol, 45: 2105-2109.

Liu W K, Chen D H, Liu Q, Liang H X, Yang Z F, Qin S, and Zhou R. 2011. Detection of human bocavirus from children and adults with acute respiratory tract illness in Guangzhou, southern China. BMC Infect Dis, 11: 345.

Mackay I M, Bielasiewicz S, Jacob K C, McQueen E, Arden K E, Nissen M D, and Sloots T P. 2006. Genetic diversity of human metapneumovirus over 4 consecutive years in Australia. J Infect Dis, 193: 1630-1633.

Mak G C, Cheng P K, and Lim W. 2011. Evaluation of Qiagen Resplex H1 for the detection of pandemic influenza A (H1N1) 2009 and influenza A (H3N2) virus. J Clin Virol, 51: 88-89.

Martin E T, Kuypers J, Wald A, and Englund J A. 2012. Multiple versus single virus respiratory infections: viral load and clinical disease severity in hospitalized children. Influenza Other Respir Viruses, 6: 71-77.

Pyre K, Berkhout B, and van der Hoek L. 2007. Identification of new human coronaviruses. Expert Rev Anti Infect Ther, 5: 245-253.

Rand K H, Rampersaud H, and Houck H J. 2011. Comparison of two multiplex methods for detection of respiratory viruses: FilmArray RP and xTAG RVP. J Clin Microbiol, 49: 2449-2453.

Ruuksen O, Lahti E, Jennings L C, and Murdoch D R. 2011. Viral pneumonia. Lancet, 377: 1264-1275.

Schindera C, Kraemer A L, Regamey N, Aebi C, Gorgievski-Hrisoho M, and Barbani M T. 2010. Immunofluorescence versus xTAG multiplex PCR for the detection of respiratory picornavirus infections in children. J Clin Virol, 48: 223-225.

Sefers S E, Rickmyre J, Blackman A, Li H, Edwards K, and Tang Y W. 2006. QIAamp MinElute virus kit effectively extracts viral nucleic acids from cerebrospinal fluids and nasopharyngeal swabs. J Clin Virol, 35: 141-146.

Sung C C, Chi H, Chiu N C, Huang D T, Weng L C, Wang N Y, and Huang F Y. 2011. Viral etiology of acute lower respiratory tract infections in hospitalized young children in Northern Taiwan. J Microbiol Immunol Infect, 44: 184-190.

Takeyama A, Hashimoto K, Sato M, Sato T, Kanno S, Takano K, Ito M, Katayose M, Nishimura H, Kawasaki Y, and Hosoya M. 2012. Rhinovirus load and disease severity in children with lower respiratory tract infections. J Med Virol, 84: 1135-1142.

Tang Y W, Sefers S E, Li H, Kohn D J, and Procop G W. 2005. Comparative evaluation of three commercial systems for nucleic acid extraction from urine specimens. J Clin Microbiol, 43: 4830-4833.

Thompson W W, Shay D K, Weintraub E, Brammer L, Cox N, Anderson L J, and Fukuda K. 2003. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA, 289: 179-186.

Torres J P, Gomez A M, Khokhar S, Bhej V G, Tagliabue C, Chang M L, Kiener P A, Revell P A, Ramilo O, and Mejias A. 2010. Respiratory syncytial virus (RSV) RNA loads in peripheral blood correlates with disease severity in mice. Respir Res, 11: 125.

van den Hoogen B G, de Jong J C, Groen J, Kuiken T, de Groot R, Fouche R A, and Osterhaus A D. 2001. A newly discovered human pneumovirus isolated from young children with respiratory tract disease. Nat Med, 7: 719-724.

van Woensel J B, van Aalderen W M, and Kimpen J L. 2003. Viral lower respiratory tract infection in infants and young children. BMJ, 327: 36-40.

Weigl J A, Puppe W, Belke O, Neususs J, Bagei F, and Schmitt H J. 2005. The descriptive epidemiology of severe lower respiratory tract infections in children in Kiel, Germany. Klin Padiatr, 217: 259-267.

Yang G, Erdman D E, Kodani M, Kools J, Bowen M D, and Fields B S. 2011. Comparison of commercial systems for extraction of nucleic acids from DNA/RNA respiratory pathogens. J Virol Methods, 171: 195-199.

Yang Z F, Zhan Y Q, Wang Y T, Luo Y, Zhou H, Li J Q, Qin S, Guan W D, Liang Z W, Zhao S S, Huang Q D, Mo Z Y, Chen J X, and Chen R C. 2010. A pathogenic and clinical study of 882 cases of adult influenza-like illness in Guangzhou. Chin J Tubere Resp Dis (in Chinese), 33: 742-745.

Zhang S, Zhang W, and Tang Y W. 2011. Molecular diagnosis of viral respiratory infections. Curr Infect Dis Rep, 13: 149-158.